Pegzilarginase: 7 agencies, 2023–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused pegzilarginase: all 3 decisive outcomes across 3 agencies were positive or positive with restrictions.
The record spans 3.3 years, opening at AWMSG (Wales) on 22 Mar 2023 and running to 2026.
No assessment is on file from PHARMAC (New Zealand), TLV (Sweden) and CIPM (Spain), each among the eight highest-volume agencies here.
Not every gap is a refusal: for pegzilarginase, 1 submission was never made — an outcome set by the company rather than the assessor.
The file is active: 7 of 7 records date from 2023 or later.
1 of these 7 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess pegzilarginase, on 22 Mar 2023; PBAC (Australia) did not open a file until 2026 — a wide spread of 3.3 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 3 of 7 dated records fall in 2024 alone.
7 of the 18 agencies in this archive hold a record for pegzilarginase.
The full ledger for pegzilarginase reads 2 recommended, 1 advice, 1 non-submission and 1 other, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| SMC (Scotland) | 9 Jun 2025 | Treatment of arginase 1 deficiency (ARG1-D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older. | not recommended | source |
| AIFA (Italy) | 8 Feb 2025 | Loargys è indicato per il trattamento del deficit di arginasi 1 (ARG1-D), noto anche come iperargininemia, in adulti, ad… | fully innovative · reimbursed class H | source |
| NYE METODER (Norway) | 20 Oct 2024 | Behandling av arginase 1-mangel (ARG1-D), også kjent som hyperargininemi, hos voksne, ungdom og barn i alderen 2 år og e… | decision recorded | source |
| G-BA (Germany) | 4 Jul 2024 | Loargys — benefit assessment §35a | added benefit: non-quantifiable (hint) | source |
| HAS (France) | 29 May 2024 | Listing (Transparency Committee) | SMR substantial · ASMR IV | source |
2 further decisions for pegzilarginase, across 2 agencies, are not shown here. They include the most recent record on file, 2026 from PBAC (Australia); its outcome is in the subscriber dataset. They link to 2 further source documents.
Related molecules
- teduglutide — same ATC class A16A — Other alimentary tract and metabolism
- sapropterin — same ATC class A16A — Other alimentary tract and metabolism
- miglustat — same ATC class A16A — Other alimentary tract and metabolism
- migalastat — same ATC class A16A — Other alimentary tract and metabolism
- cerliponase alfa — same ATC class A16A — Other alimentary tract and metabolism
- givosiran — same ATC class A16A — Other alimentary tract and metabolism
Coverage: 7 decisions for pegzilarginase from 7 agencies, 2023 to 2026. Data to 7 Sep 2026. ATC class A16A — Other alimentary tract and metabolism. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.